{"id":"NCT01584232","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus","officialTitle":"A Phase 3 Study of LY2189265 Compared to Insulin Glargine in Patients With Type 2 Diabetes Mellitus on a Sulfonylurea and/or Biguanide","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-04","primaryCompletion":"2013-07","completion":"2013-07","firstPosted":"2012-04-24","resultsPosted":"2014-10-20","lastUpdate":"2014-10-20"},"enrollment":361,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"LY2189265","otherNames":["Dulaglutide"]},{"type":"DRUG","name":"Insulin glargine","otherNames":[]},{"type":"DRUG","name":"Sulfonylureas (SU)","otherNames":[]},{"type":"DRUG","name":"Biguanide (BG)","otherNames":[]}],"arms":[{"label":"LY2189265 + OAM","type":"EXPERIMENTAL"},{"label":"Insulin glargine + OAM","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 (dulaglutide) in participants with type 2 diabetes mellitus taking an oral antihyperglycemic medication (OAM).","primaryOutcome":{"measure":"Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks","timeFrame":"Baseline, 26 weeks","effectByArm":[{"arm":"LY2189265 + OAM","deltaMin":-1.44,"sd":0.05},{"arm":"Insulin Glargine + OAM","deltaMin":-0.9,"sd":0.05}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":15,"countries":["Japan"]},"refs":{"pmids":["28606095"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":181},"commonTop":["Nasopharyngitis","Diarrhoea","Constipation","Nausea","Hypertension"]}}